

GLAXOSMITHKLINE PLC
Form 6-K
August 10, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 10 August 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.1861	8 (partnership shares)
£15.1861	8 (matching shares)

Aggregated information

- d) Aggregated volume 16 Ordinary Shares
- Price £15.1861
- e) Date of the transaction 2017-08-09
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Manufacturing & Supply
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
 where transaction(s) has been conducted Ordinary shares of 25 pence each
 ('Ordinary Shares')
- a) Description of the financial instrument
 ISIN: GB0009252882
 Acquisition of Ordinary Shares
 under the Company's Share
 Reward Plan
- b) Nature of the transaction
- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £15.1861 8 (partnership shares)
 £15.1861 8 (matching shares)
- Aggregated information
- d) Aggregated volume 16 Ordinary Shares
 Price £15.1861
- e) Date of the transaction 2017-08-09
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S Dingemans
 b) Position/status Chief Financial Officer
 c) Initial notification/
 amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
 where transaction(s) has been conducted Ordinary shares of 25 pence each
 ('Ordinary Shares')
- a) Description of the financial instrument
 ISIN: GB0009252882
 Acquisition of Ordinary Shares
 under the Company's Share
 Reward Plan
- b) Nature of the transaction
- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £15.1861 8 (partnership shares)
 £15.1861 8 (matching shares)
- d) Aggregated information

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated volume	16 Ordinary Shares
Price	£15.1861
e) Date of the transaction	2017-08-09
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr N Hirons
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each (‘Ordinary Shares’)
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £15.1861 8 (partnership shares) £15.1861 8 (matching shares)
Aggregated information	
d) Aggregated volume	16 Ordinary Shares
Price	£15.1861
e) Date of the transaction	2017-08-09
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr D S Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
 where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each
 ('Ordinary Shares')
- b) Nature of the transaction ISIN: GB0009252882
 Acquisition of Ordinary Shares
 under the Company's Share
 Reward Plan
- c) Price(s) and volume(s) Price(s) Volume(s)
 £15.1861 8 (partnership shares)
 £15.1861 8 (matching shares)
- Aggregated information
- d) Aggregated volume 16 Ordinary Shares
 Price £15.1861
- e) Date of the transaction 2017-08-09
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/
 amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
 where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each
 ('Ordinary Shares')
- b) Nature of the transaction ISIN: GB0009252882
 Acquisition of Ordinary Shares
 under the Company's Share
 Reward Plan
- c) Price(s) and volume(s) Price(s) Volume(s)
 £15.1861 8 (partnership shares)
 £15.1861 8 (matching shares)
- d) Aggregated information

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated volume	16 Ordinary Shares
Price	£15.1861
e) Date of the transaction	2017-08-09
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr P C Thomson
b) Position/status	President, Global Affairs
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s)	Price(s)